Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1999 Mar 1;338(Pt 2):281–287.

Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.

M C Jong 1, K W van Dijk 1, V E Dahlmans 1, H Van der Boom 1, K Kobayashi 1, K Oka 1, G Siest 1, L Chan 1, M H Hofker 1, L M Havekes 1
PMCID: PMC1220053  PMID: 10024503

Abstract

We have shown previously that human apolipoprotein (apo)C1 transgenic mice exhibit hyperlipidaemia, due primarily to an impaired clearance of very-low-density lipoprotein (VLDL) particles from the circulation. In the absence of at least the low-density-lipoprotein receptor (LDLR), it was shown that APOC1 overexpression in transgenic mice inhibited the hepatic uptake of VLDL via the LDLR-related protein. In the present study, we have now examined the effect of apoC1 on the binding of lipoproteins to both the VLDL receptor (VLDLR) and the LDLR. The binding specificity of the VLDLR and LDLR for apoC1-enriched lipoprotein particles was examined in vivo through adenovirus-mediated gene transfer of the VLDLR and the LDLR [giving rise to adenovirus-containing (Ad)-VLDLR and Ad-LDLR respectively] in APOC1 transgenic mice, LDLR-deficient (LDLR-/-) mice and wild-type mice. Remarkably, Ad-VLDLR treatment did not reduce hyperlipidaemia in transgenic mice overexpressing human APOC1, irrespective of both the level of transgenic expression and the presence of the LDLR, whereas Ad-VLDLR treatment did reverse hyperlipidaemia in LDLR-/- and wild-type mice. On the other hand, Ad-LDLR treatment strongly decreased plasma lipid levels in these APOC1 transgenic mice. These results suggest that apoC1 inhibits the clearance of lipoprotein particles via the VLDLR, but not via the LDLR. This hypothesis is corroborated by in vitro binding studies. Chinese hamster ovary (CHO) cells expressing the VLDLR (CHO-VLDLR) or LDLR (CHO-LDLR) bound less APOC1 transgenic VLDL than wild-type VLDL. Intriguingly, however, enrichment with apoE enhanced dose-dependently the binding of wild-type VLDL to CHO-VLDLR cells (up to 5-fold), whereas apoE did not enhance the binding of APOC1 transgenic VLDL to these cells. In contrast, for binding to CHO-LDLR cells, both wild-type and APOC1 transgenic VLDL were stimulated upon enrichment with apoE. From these studies, we conclude that apoC1 specifically inhibits the apoE-mediated binding of triacylglycerol-rich lipoprotein particles to the VLDLR, whereas apoC1-enriched lipoproteins can still bind to the LDLR. The variability in specificity of these lipoprotein receptors for apoC1-containing lipoprotein particles provides further evidence for a regulatory role of apoC1 in the delivery of lipoprotein constituents to different tissues on which these receptors are located.

Full Text

The Full Text of this article is available as a PDF (160.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battey F. D., Gåfvels M. E., FitzGerald D. J., Argraves W. S., Chappell D. A., Strauss J. F., 3rd, Strickland D. K. The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor. J Biol Chem. 1994 Sep 16;269(37):23268–23273. [PubMed] [Google Scholar]
  2. Beisiegel U., Heeren J. Lipoprotein lipase (EC 3.1.1.34) targeting of lipoproteins to receptors. Proc Nutr Soc. 1997 Jul;56(2):731–737. doi: 10.1079/pns19970073. [DOI] [PubMed] [Google Scholar]
  3. Bilheimer D. W., Eisenberg S., Levy R. I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972 Feb 21;260(2):212–221. doi: 10.1016/0005-2760(72)90034-3. [DOI] [PubMed] [Google Scholar]
  4. Clavey V., Lestavel-Delattre S., Copin C., Bard J. M., Fruchart J. C. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):963–971. doi: 10.1161/01.atv.15.7.963. [DOI] [PubMed] [Google Scholar]
  5. Frykman P. K., Brown M. S., Yamamoto T., Goldstein J. L., Herz J. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8453–8457. doi: 10.1073/pnas.92.18.8453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gåfvels M. E., Caird M., Britt D., Jackson C. L., Patterson D., Strauss J. F., 3rd Cloning of a cDNA encoding a putative human very low density lipoprotein/apolipoprotein E receptor and assignment of the gene to chromosome 9pter-p23. Somat Cell Mol Genet. 1993 Nov;19(6):557–569. doi: 10.1007/BF01233382. [DOI] [PubMed] [Google Scholar]
  7. Hendriks W. L., van der Boom H., van Vark L. C., Havekes L. M. Lipoprotein lipase stimulates the binding and uptake of moderately oxidized low-density lipoprotein by J774 macrophages. Biochem J. 1996 Mar 1;314(Pt 2):563–568. doi: 10.1042/bj3140563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Herz J., Gerard R. D. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2812–2816. doi: 10.1073/pnas.90.7.2812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ishibashi S., Brown M. S., Goldstein J. L., Gerard R. D., Hammer R. E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993 Aug;92(2):883–893. doi: 10.1172/JCI116663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jong M. C., Dahlmans V. E., van Gorp P. J., Breuer M. L., Mol M. J., van der Zee A., Frants R. R., Hofker M. H., Havekes L. M. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):934–940. doi: 10.1161/01.atv.16.8.934. [DOI] [PubMed] [Google Scholar]
  11. Jong M. C., Dahlmans V. E., van Gorp P. J., van Dijk K. W., Breuer M. L., Hofker M. H., Havekes L. M. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 1996 Nov 15;98(10):2259–2267. doi: 10.1172/JCI119036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jong M. C., Gijbels M. J., Dahlmans V. E., Gorp P. J., Koopman S. J., Ponec M., Hofker M. H., Havekes L. M. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest. 1998 Jan 1;101(1):145–152. doi: 10.1172/JCI791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jong M. C., van Ree J. H., Dahlmans V. E., Frants R. R., Hofker M. H., Havekes L. M. Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. Biochem J. 1997 Jan 15;321(Pt 2):445–450. doi: 10.1042/bj3210445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kobayashi K., Oka K., Forte T., Ishida B., Teng B., Ishimura-Oka K., Nakamuta M., Chan L. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem. 1996 Mar 22;271(12):6852–6860. doi: 10.1074/jbc.271.12.6852. [DOI] [PubMed] [Google Scholar]
  15. Kowal R. C., Herz J., Weisgraber K. H., Mahley R. W., Brown M. S., Goldstein J. L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990 Jun 25;265(18):10771–10779. [PubMed] [Google Scholar]
  16. Kozarsky K. F., Jooss K., Donahee M., Strauss J. F., 3rd, Wilson J. M. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet. 1996 May;13(1):54–62. doi: 10.1038/ng0596-54. [DOI] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Niemeier A., Gàfvels M., Heeren J., Meyer N., Angelin B., Beisiegel U. VLDL receptor mediates the uptake of human chylomicron remnants in vitro. J Lipid Res. 1996 Aug;37(8):1733–1742. [PubMed] [Google Scholar]
  19. Patel D. D., Forder R. A., Soutar A. K., Knight B. L. Synthesis and properties of the very-low-density-lipoprotein receptor and a comparison with the low-density-lipoprotein receptor. Biochem J. 1997 Jun 1;324(Pt 2):371–377. doi: 10.1042/bj3240371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Quarfordt S. H., Michalopoulos G., Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem. 1982 Dec 25;257(24):14642–14647. [PubMed] [Google Scholar]
  21. Rohlmann A., Gotthardt M., Hammer R. E., Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998 Feb 1;101(3):689–695. doi: 10.1172/JCI1240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sakai J., Hoshino A., Takahashi S., Miura Y., Ishii H., Suzuki H., Kawarabayasi Y., Yamamoto T. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem. 1994 Jan 21;269(3):2173–2182. [PubMed] [Google Scholar]
  23. Sehayek E., Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991 Sep 25;266(27):18259–18267. [PubMed] [Google Scholar]
  24. Shachter N. S., Ebara T., Ramakrishnan R., Steiner G., Breslow J. L., Ginsberg H. N., Smith J. D. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J Clin Invest. 1996 Aug 1;98(3):846–855. doi: 10.1172/JCI118857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Simonsen A. C., Heegaard C. W., Rasmussen L. K., Ellgaard L., Kjøller L., Christensen A., Etzerodt M., Andreasen P. A. Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of M(r) 40,000 receptor associated protein. FEBS Lett. 1994 Nov 14;354(3):279–283. doi: 10.1016/0014-5793(94)01138-9. [DOI] [PubMed] [Google Scholar]
  26. Swaney J. B., Weisgraber K. H. Effect of apolipoprotein C-I peptides on the apolipoprotein E content and receptor-binding properties of beta-migrating very low density lipoproteins. J Lipid Res. 1994 Jan;35(1):134–142. [PubMed] [Google Scholar]
  27. Takahashi S., Kawarabayasi Y., Nakai T., Sakai J., Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9252–9256. doi: 10.1073/pnas.89.19.9252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Takahashi S., Suzuki J., Kohno M., Oida K., Tamai T., Miyabo S., Yamamoto T., Nakai T. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem. 1995 Jun 30;270(26):15747–15754. doi: 10.1074/jbc.270.26.15747. [DOI] [PubMed] [Google Scholar]
  29. Van Eck M., Herijgers N., Yates J., Pearce N. J., Hoogerbrugge P. M., Groot P. H., Van Berkel T. J. Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3117–3126. doi: 10.1161/01.atv.17.11.3117. [DOI] [PubMed] [Google Scholar]
  30. Weisgraber K. H., Mahley R. W., Kowal R. C., Herz J., Goldstein J. L., Brown M. S. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990 Dec 25;265(36):22453–22459. [PubMed] [Google Scholar]
  31. Windler E., Havel R. J. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985 May;26(5):556–565. [PubMed] [Google Scholar]
  32. Wyne K. L., Pathak K., Seabra M. C., Hobbs H. H. Expression of the VLDL receptor in endothelial cells. Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):407–415. doi: 10.1161/01.atv.16.3.407. [DOI] [PubMed] [Google Scholar]
  33. Yokode M., Hammer R. E., Ishibashi S., Brown M. S., Goldstein J. L. Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors. Science. 1990 Nov 30;250(4985):1273–1275. doi: 10.1126/science.2244210. [DOI] [PubMed] [Google Scholar]
  34. van Dijk K. W., van Vlijmen B. J., van der Zee A., van't Hof B., van der Boom H., Kobayashi K., Chan L., Havekes L. M., Hofker M. H. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor. Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):7–12. doi: 10.1161/01.atv.18.1.7. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES